Navigation Links
Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
Date:2/19/2013

AUSTIN, Texas, Feb. 19, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and vascular medicine, has been invited to participate in Lazard Capital Market's 5th Annual Medical Technology Snowbird Conference. The conference is being held at the Cliff Lodge Snowbird Ski & Summer Resort in Snowbird, Utah from February 27 - March 1, 2013.

Vermillion's Interim CEO Bruce A. Huebner is scheduled to participate in one-on-one meetings with institutional investors to be held throughout the day on Wednesday, February 27, 2013. He will discuss the company's initiatives to drive market adoption of OVA1®, the first FDA-cleared blood test for the pre-surgical diagnosis of ovarian masses using a unique multi-marker algorithm.  

For more information about the conference or to schedule a one-on-one meeting with Vermillion management, contact your Lazard representative.

About Lazard Capital Markets
Lazard Capital Markets is a growth-oriented full service broker-dealer with a unique position in today's capital markets. The company's institutional clients value its focused, action-oriented proprietary research, which is based on deep domain expertise in the Healthcare, Consumer, Energy, Technology and Transportation sectors. The company's Sales and Trading professionals have long-standing relationships with over 600 institutional accounts, and, with an average of 15 years of experience, have an intimate knowledge of our clients' investment objectives. Finally, the company's relationship with Lazard, an international investment bank, which operates in 39 cities across 21 countries, provides the company with unparalleled global connections. For more information, visit www.lazardcap.com.

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health. Additional information about Vermillion can be found at www.vermillion.com.

Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 949-574-3860
vrml@liolios.com


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion Sharpens Focus and Streamlines Operations in 2012
2. Vermillion Reports Fourth Quarter and Full Year 2011 Results
3. Vermillion Reports First Quarter 2012 Results
4. Concerned Stockholders Launch Save Vermillion! Website: www.savevrml.com
5. ViroPharma to Participate in Two December Healthcare Investor Conferences
6. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
7. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
8. Genomind to Participate in National Alliance on Mental Illness (NAMI) 2012 National Convention
9. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
10. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , ... February 21, 2017 , ... ... organizations to build connected digital health applications, announced a partnership with Redox, a ... to seamlessly connect to many clinical systems while keeping data secure in the ...
(Date:2/21/2017)... ... February 21, 2017 , ... Genedata, a leading provider ... announced the establishment of Genedata Limited as a new subsidiary in the United ... in life science informatics. Creating the UK subsidiary reinforces Genedata’s commitment to collaborate ...
(Date:2/21/2017)... ... February 21, 2017 , ... The medical potential of stem cells is both ... of medicine, due to their differentiating characteristics. Stem cells are unique as the have ... be induced to become tissue or organic-specific cells with special functions. , Stem ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... manufacturing facility at its headquarters laboratory in Poway, California. Based upon 12 ... of both in-house personnel and consultants, VetStem constructed and validated a state-of-the-art GMP ...
Breaking Biology Technology:
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
(Date:2/7/2017)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the latest release ... flexible and award winning eClinical solution, is now available ... is a proven Software-as-a-Service (SaaS) clinical research technology platform ... also delivers an entire suite of eClinical tools to ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
Breaking Biology News(10 mins):